To include your compound in the COVID-19 Resource Center, submit it here.

Spark reports Factor VIII activity data from Phase I/II of SPK-8011 in hemophilia A

Spark Therapeutics Inc. (NASDAQ:ONCE) reported additional Phase I/II data on Factor VIII activity levels for its gene therapy to treat hemophilia A. Data were presented at the American Society of Hematology meeting in Atlanta (see BioCentury, Dec. 8).

In the open-label, international

Read the full 419 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE